A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an incr ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Research reveals major gap between weight-loss surgery and GLP-1 drugs, with real-world results of injectable medications falling short of clinical trial outcomes.

Findings of study demonstrating the effectiveness of combining bimagrumab – a drug designed to combat muscle loss – with a common GLP-1 receptor agonist (RA), semaglutide, were presented ...

Beyond GLP-1: Frozen meal newcomer marries comfort and nutrient-density for health-conscious consumers By Elizabeth Crawford ...

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity.

LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products In addition to persistence and adherence insights, the Year-3 study found 38% of individuals switched GLP ...